Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2/3 2Phase 2 2Phase 3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × Fish Oils × Clear all
NCT01869764 2019-10-30

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

Wake Forest University Health Sciences

Phase 2 Completed
57 enrolled 8 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Breast Neoplasms, Male

NCT01325584 2018-08-07

Compassionate Use of OmegavenĀ® in the Treatment of Parenteral Nutrition Induced Hepatic Injury

Midwestern Regional Medical Center

Phase 2 Terminated
12 enrolled 10 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔